https://maxwellbiosciences.com/articles/news daily 0.75 2026-04-01 https://maxwellbiosciences.com/articles/news/rethinking-the-resilient-brain-the-new-frontier-of-immuno-neurology monthly 0.5 2026-04-01 https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/4520383c-aa17-4875-b3a7-53d21846bac5/EBV-MS-graphic.jpg News - Rethinking the Resilient Brain: The New Frontier of Immuno-Neurology - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/69beaddf-b1f3-4f11-bcaa-00f41ed351fb/LL37-Alzheimers-graphic.jpg News - Rethinking the Resilient Brain: The New Frontier of Immuno-Neurology - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/5a8b3ff3-0cc3-4580-aa8e-ad47621586b4/Claromer-Membrane-graphic.jpg News - Rethinking the Resilient Brain: The New Frontier of Immuno-Neurology - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/b6497620-2a76-4b20-82dc-5ad39be6deaf/LeakyGut-Neurotoxicity-graphic.jpg News - Rethinking the Resilient Brain: The New Frontier of Immuno-Neurology - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/6a7018e0-af4d-4d57-ab1c-06298f80e28a/Scotch-Signature-small.png News - Rethinking the Resilient Brain: The New Frontier of Immuno-Neurology - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://maxwellbiosciences.com/articles/news/fighting-neonatal-sepsis-in-india monthly 0.5 2026-03-13 https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/726bea46-9471-4e98-9f1e-1b7eba6757ca/Havih-FlagBaby.jpg News - Fighting Neonatal Sepsis in India - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/a56b2eb5-f683-45d5-a73e-712477a71958/Havih-Sepsis-GlobalMap.jpg News - Fighting Neonatal Sepsis in India - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/6a7018e0-af4d-4d57-ab1c-06298f80e28a/Scotch-Signature-small.png News - Fighting Neonatal Sepsis in India - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://maxwellbiosciences.com/articles/news/havihpartnershipuspr monthly 0.5 2026-03-09 https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/b172fb2f-aae4-407f-91de-86fad2c60df9/MoU+India+photo.png News - Maxwell Biosciences Subsidiary Havih Announces Partnership with the Government of Andhra Pradesh Research and development of novel pharma IP could be a key component for a stronger pharma workforce in India. https://maxwellbiosciences.com/articles/news/havihpartnershipindiapr monthly 0.5 2026-03-09 https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/b172fb2f-aae4-407f-91de-86fad2c60df9/MoU+India+photo.png News - Havih, a Maxwell Biosciences Subsidiary, Announces Partnership with the Government of Andhra Pradesh Research and development of novel pharma IP could be a key component for a stronger pharma workforce in India. https://maxwellbiosciences.com/articles/news/formeruscongressmanjoinsmaxwellboard monthly 0.5 2026-03-09 https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/46e0b999-fdf1-410d-ba5e-4e8972b20542/Brad+Wenstrup.jpg News - Former US Congressman Dr. Brad Wenstrup Joins Maxwell Board COL (Ret.) Brad Wenstrup, DPM https://maxwellbiosciences.com/articles/news/scientistappreciationday monthly 0.5 2026-03-09 https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/cc6bfad0-8a14-41a0-90cc-67b5aa8e2a6b/ScientistAppreciationDay.jpg News - Maxwell Biosciences Marks Scientist Appreciation Day With Renewed Call to Recognize Scientists https://maxwellbiosciences.com/articles/news/fundingroundclosed monthly 0.5 2026-03-09 https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/855aa268-e310-4820-a1b0-84229062afd4/Logo++%281%29.png News - Maxwell Biosciences Announces Closing of $20M Financing Round https://maxwellbiosciences.com/articles/news/aiannouncement monthly 0.5 2026-03-09 https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/f98bd31a-226e-4730-846f-984f2321c774/AI+Announcement.png News - Maxwell Biosciences Announces AI Department & Hiring of Jon McClure https://maxwellbiosciences.com/articles/news/cosmeticsannouncement monthly 0.5 2026-03-09 https://maxwellbiosciences.com/articles/news/7th-military-agreement monthly 0.5 2026-03-09 https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/b7c36277-f90a-48db-a997-a5672de8968a/PR+Image+CRADA+6.jpg News - Maxwell Biosciences Secures Anti-Diarrheal US Military Agreement - Make it stand out E. Coli bacteria in blood https://maxwellbiosciences.com/articles/news/contract-pharma-interview monthly 0.5 2026-03-09 https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/1ecc1a03-7515-4df7-98a3-5b466821ed06/contract+pharma+image.png News - Combating Infectious Diseases: Maxwell Biosciences Partners with U.S. Military  - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://maxwellbiosciences.com/articles/news/ceo-longevity-interview monthly 0.5 2026-03-09 https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/382c2c72-5bd9-491e-b301-36af1740258b/Screenshot+2025-03-25+at+12.36.31+PM.png News - Longevity.IO Interview with Maxwell CEO Joshua 'Scotch' McClure: How Claromers™ Could Revolutionize Longevity and Fight Infectious Disease - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/aba199fc-e3a0-4db7-a1c0-21c98b7cd626/Biomass_v9.jpg News - Longevity.IO Interview with Maxwell CEO Joshua 'Scotch' McClure: How Claromers™ Could Revolutionize Longevity and Fight Infectious Disease - Make it stand out Image Credit: All the Biomass of Earth, in One Graphic https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/dad96ce7-76a8-41f8-924a-3068cd8508ac/_Maxwell+New+Master+gfx+v1NC.2503m25v2.png News - Longevity.IO Interview with Maxwell CEO Joshua 'Scotch' McClure: How Claromers™ Could Revolutionize Longevity and Fight Infectious Disease - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://maxwellbiosciences.com/articles/news/us-army-agreement monthly 0.5 2026-03-09 https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/5eded927-bdd4-4270-84b0-a5fda7fa5c5d/CRADA+8+Image+for+Newsfile+PR.jpg News - Maxwell Biosciences Secures US Military Agreement to Research Scientific Aspects of Claromer™ Technology - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://maxwellbiosciences.com/articles/news/dengue-agreement monthly 0.5 2026-03-09 https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/295b056d-19d8-4b9c-afa6-f67013ad28ad/HighResDengueLabImage.png News - Maxwell Biosciences Secures US Military Research Agreement to Combat Dengue Fever - Make it stand out Scientist examines dengue virus in laboratory https://maxwellbiosciences.com/articles/news/maxwell-biosciences-announces-appointment-of-jos-antonio-alas-to-its-board-of-directors monthly 0.5 2026-03-09 https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/de00dc11-99a1-4d17-b579-9fe8114cc87a/Jose+Antonio+Alas.png News - Maxwell Biosciences Announces Appointment of José Antonio Alas to Its Board of Directors José Antonio Alas https://maxwellbiosciences.com/articles/news/maxwell-biosciences-announces-mtec-award monthly 0.5 2026-03-09 https://maxwellbiosciences.com/articles/news/maxwell-biosciences-enters-crada-with-usamriid-n4lm3 monthly 0.5 2026-03-09 https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/0690f520-43c2-4553-955c-87c7f458a0f5/Copy+of+Maxwell+Press+Release+Images++%282%29.png News - Maxwell Biosciences Enters Second CRADA with USAMRIID to Test Claromer Compounds as Potential Therapeutics for Viral and Bacterial Pathogens - Make it stand out USAMRIID to study antiviral and antibacterial activity of Claromer technology against national priority biodefense threats https://maxwellbiosciences.com/articles/news/maxwell-biosciences-ceo-named-top25healthcareexecutive monthly 0.5 2026-03-09 https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/cda768e6-66f2-4055-8cfa-dbdb5653e2df/Healthcare+Technology+Social+Media.png News - Maxwell Biosciences CEO J. Scotch McClure Named Top 25 Executive in Biotechnology - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://maxwellbiosciences.com/articles/news/maxwell-biosciences-announces-promising-activity-of-claromer-compound-against-ebola-virus-in-a-research-study monthly 0.5 2026-03-09 https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/f5cacfb4-4ac8-4540-b886-e5ae55ea4282/Second+Crada.png News - Maxwell Biosciences Announces Promising Activity of Claromer Compound Against Ebola Virus in a Research Study - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://maxwellbiosciences.com/articles/news/maxwell-biosciences-enters-crada-with-usamriid monthly 0.5 2026-03-09 https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/962c4ecc-a6f8-4886-8f11-8764af6bba6a/Second+Crada.jpg News - Maxwell Biosciences Enters CRADA with USAMRIID to Test Claromer Compounds as Potential Therapeutics for Viral Pathogens, Including Hemorrhagic Fever Ebola Viral Disease, and Other Biodefense Pathogens - Make it stand out USAMRIID to study antiviral activity of Claromer™ technology against national priority biodefense threats https://maxwellbiosciences.com/articles/news/maxwell-biosciences-appoints-major-general-ret-barb-holcomb-rn-bsn-msn-to-its-board-of-directors monthly 0.5 2026-03-09 https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/c02d15e2-1c93-44bf-897e-8287da1baa56/Barb+Holcomb+photo+900.jpg News - Maxwell Biosciences Appoints Major General (Ret.) Barb Holcomb, RN, BSN, MSN to Its Board of Directors - Make it stand out Major General (Ret.) Barb Holcomb, RN, BSN, MSN https://maxwellbiosciences.com/articles/news/biotech-startup-maxwell-biosciences-announces-breakthrough-antiviral-research monthly 0.5 2026-03-09 https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/9d7a826f-7cdb-4d09-9b38-3c9fd0807dfd/images_large_id3c00063_0007.jpeg News - Maxwell Biosciences Announces Publication of Mechanism of Action Study: Claromer Compounds Target Pathogens by Disrupting Their Membranes - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://maxwellbiosciences.com/articles/news/biotech-startup-maxwell-biosciences-selected-to-present-at-the-angel-capital-association-2023-summit monthly 0.5 2026-03-09 https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/1731124793386-E1EGRW813W4J3M3ZMOWX/Angel+Capital+Association.png News - Biotech Startup Maxwell Biosciences Selected to Present at the Angel Capital Association 2023 Summit - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://maxwellbiosciences.com/articles/news/maxwell-biosciences-announces-the-appointment-of-maxie-mcfarland-mba-as-senior-vice-president-of-corporate-development-and-investor-relations monthly 0.5 2026-03-09 https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/1682545481706-HFS50A192P1W8ICMKKHQ/maxie+image.jpeg News - Maxwell Biosciences Announces the Appointment of Maxie McFarland, MBA, as Senior Vice President of Corporate Development and Investor Relations https://maxwellbiosciences.com/articles/news/maxwell-biosciences-names-two-biotech-leaders-board-of-directors monthly 0.5 2026-03-09 https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/1667787947819-LJYF0EZ7571JE941N49O/Screen+Shot+2022-11-06+at+8.25.17+PM.png News - Maxwell Biosciences Names Two Biotech Leaders to Its Board of Directors https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/1667787961362-X3LOSWPUIK8C37DRY43Y/Screen+Shot+2022-11-06+at+8.25.34+PM.png News - Maxwell Biosciences Names Two Biotech Leaders to Its Board of Directors https://maxwellbiosciences.com/articles/news/optionsxi-data monthly 0.5 2025-03-04 https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/1664250122315-WP4QIQH53ZRT3C37XGUH/sr_1510285.jpeg News - Maxwell Biosciences Announces In Vivo and In Vitro Data on CLAROMER™ Platform’s Ability to Treat and Prevent SARS-CoV-2 and Other Respiratory Viruses at OPTIONS XI Conference - Make it stand out Learn more about the Options XI conference here. https://maxwellbiosciences.com/articles/news/optionsxi monthly 0.5 2026-03-09 https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/1664250122315-WP4QIQH53ZRT3C37XGUH/sr_1510285.jpeg News - Maxwell Biosciences to Present Data on CLAROMER™ Platform’s Treatment and Prevention of SARS-CoV-2 and Other Respiratory Viruses at OPTIONS XI Conference - Make it stand out Learn more about the Options XI conference here. https://maxwellbiosciences.com/articles/news/maxwell-biosciences-expands-leadership-team-with-the-appointment-of-three-senior-executives monthly 0.5 2026-03-09 https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/1664044287059-UUIQ5RNCEHR1OPZF81KT/Tony_Verco_Headshot.jpeg News - Maxwell Biosciences Expands Leadership Team with the Appointment of Three Senior Executives https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/1664044288104-JZ3VY7KG2YTGFWRUJ3D5/Don_Treacy_Headshot.jpeg News - Maxwell Biosciences Expands Leadership Team with the Appointment of Three Senior Executives https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/1664044290690-1PHK30UB3RG9Z46WNWCU/Beth_Burnside_Headshot.jpeg News - Maxwell Biosciences Expands Leadership Team with the Appointment of Three Senior Executives https://maxwellbiosciences.com/articles/news/maxwell-biosciences-announces-the-appointment-of-edward-rudnic-phd-as-chief-operating-officer monthly 0.5 2026-03-09 https://maxwellbiosciences.com/articles/news/maxwell-biosciences-raises-108-million-in-oversubscribed-seed-round monthly 0.5 2026-03-09 https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/2cc52ed4-db23-4a2b-85a7-84663b43541c/Copy+of+Maxwell+Press+Release+Images++%283%29.png News - Maxwell Biosciences Raises $10.8 Million in Oversubscribed Seed Round - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://maxwellbiosciences.com/articles/news/texas-life-science-forum-awards-maxwell-biosciences-most-promising-2022-life-sciences-company monthly 0.5 2026-03-09 https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/aeb5f158-2a31-4e43-ad9f-fe82be2b7950/2022+Texas+Life+Science+Forum+-+Most+Promising+Awardees.JPG News - Maxwell Biosciences Awarded “Most Promising” 2022 Life Sciences Company in Texas Competition - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://maxwellbiosciences.com/articles/news/new-research-published-in-acs-infectious-diseases-examines-impact-of-self-assembly-of-antimicrobial-peptoids-on-eskape-bacterial-pathogens monthly 0.5 2026-03-09 https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/15c5b38d-9037-4238-9c52-4710ce523037/largecover.jpeg News - New Research Published in ACS Infectious Diseases Examines Impact of Self-Assembly of Antimicrobial Peptoids on ESKAPE Bacterial Pathogens - Make it stand out Read the study here. https://maxwellbiosciences.com/articles/news/turning-natures-virus-fighters-into-powerful-drugs-synthetic-peptoids-to-cure-diseases monthly 0.5 2026-03-09 https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/1625418414642-JS4AZZR4US46MHJO9KNF/Screen+Shot+2021-07-04+at+12.05.09+PM.png News - Turning Nature’s Virus Fighters Into Powerful Drugs: Synthetic “Peptoids” to Cure Diseases - Make it stand out Read the full article at SciTechDaily. https://maxwellbiosciences.com/articles/news/pharmashots-viewpoints-interview-maxwell-biosciences-dr-gill-diamond-and-joshua-mcclure-share-insights-novel-peptoids-with-potent-antiviral-activity-against-hsv-1-and-sars-cov-2 monthly 0.5 2026-03-09 https://maxwellbiosciences.com/articles/news/a-bioengineer-aims-to-turn-natures-virus-into-powerful-drugs monthly 0.5 2026-03-09 https://maxwellbiosciences.com/articles/news/maxwell-biosciences-announces-the-claromer-brand-biotech-therapeutics-platform-as-it-advances-toward-clinical-trials monthly 0.5 2026-03-09 https://maxwellbiosciences.com/articles/news/david-evans-shaw-invests-in-maxwell-biosciences-to-advance-the-new-class-of-antiviral-drugs monthly 0.5 2026-03-09 https://maxwellbiosciences.com/articles/news/new-research-published-in-pharmaceuticals-mdpi-demonstrates-that-several-peptoids-exhibit-potent-in-vitro-antiviral-activity-against-both-hsv-1-and-sars-cov-2 monthly 0.5 2026-03-09 https://maxwellbiosciences.com/articles/news/npr-webcast-science-rhetoric-kuts-views-and-brews monthly 0.5 2026-03-09 https://maxwellbiosciences.com/articles/news/media-advisorymaxwell-biosciences-to-present-at-the-upcoming-2021-spring-private-company-showcase-hosted-by-credit-suisse-solebury-trout-and-cooley monthly 0.5 2026-03-09 https://maxwellbiosciences.com/articles/news/21621-press-release-maxwell-biosciences-appoints-sheetal-vali-phd-as-director-of-drug-development monthly 0.5 2026-03-09 https://maxwellbiosciences.com/articles/news/maxwell-focus-next-generation-anti-infectives monthly 0.5 2026-03-09 https://maxwellbiosciences.com/articles/news/category/Newsletter monthly 0.5 https://maxwellbiosciences.com/articles/news/category/News monthly 0.5 https://maxwellbiosciences.com/articles/news/category/Podcast monthly 0.5 https://maxwellbiosciences.com/articles/news/category/Press+Release monthly 0.5 https://maxwellbiosciences.com/articles/news/category/Interview monthly 0.5 https://maxwellbiosciences.com/articles/science daily 0.75 2021-06-15 https://maxwellbiosciences.com/articles/science/maxwell-peptoids-active-against-herpes-simplex-1-hsv-1 monthly 0.5 2020-08-20 https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/1591670977770-P9QKOAR586DGDJS4DNQN/Screen-Shot-2020-05-05-at-8.26.06-AM.png Science - Maxwell Peptoids Active Against Herpes Simplex 1 (HSV-1) Illustration: Herpes Simplex Virus Architecture and Market Size (2027) https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/1591671004866-DMZV538HFPCQBMIWCNIE/HSV-1-In-Vitro-Test-UoL.png Science - Maxwell Peptoids Active Against Herpes Simplex 1 (HSV-1) https://maxwellbiosciences.com/articles/science/next-generation-virucides-peptoids monthly 0.5 2020-08-20 https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/1591670519505-JHN7PGJJ511CXBGCOKPG/peptoids.gif Science - Next Generation Virucides – Peptoids https://maxwellbiosciences.com/home daily 1.0 2025-12-19 https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/9c601ea1-971d-421c-a4dd-e0fdade6fe7d/One+Drug+for+Many+Bugs+Chart.png https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/1689184663994-BTH6G5K2ZT15TPV7DE8P/image-asset.jpeg https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/41b76cc7-26fa-4227-b34b-c997fbd289c3/Antiviral+Therapeutic+Efficacy+Table https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/1592418162810-14J3JFSSAPEYVNJSCGRH/Female%2BScientist%2BImage.jpg Maxwell Biosciences https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/1592420361434-HKQKYWD5TB5UBFJ3YI4L/The-future-of-the-small-molecule-Increased-complexity-and-biologic-pairings-says-industry_wrbm_large.jpg Maxwell Biosciences https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/1592418258977-O29THCV71GE5TGLVOCZI/SARS-CoV-2%252525252Bhigh%252525252Bres%252525252Bimage%252525252Bblue%252525252Byellow.jpg Maxwell Biosciences https://maxwellbiosciences.com/technology daily 0.75 2024-11-14 https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/1690806771362-482NN8IIWGWA0JR4QOE0/image-asset.jpeg Technology - A Synthetic Immune System Maxwell’s CLAROMER® brand next gen anti-infectives safely destroy a broad spectrum of bacteria, fungi and viruses, as shown in preclinical animal studies and imaging confirmation of all three types of pathogens. https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/1617052023553-VIVMMGXWPADU0T7MKFWC/Claromer+stability+vs+peptide.png Technology - Maxwell’s CLAROMER® brand anti-infectives are a completely new drug class. They have the stability and potency of small molecules; yet the powerful dynamic functions of peptides. Claromers are helical small molecules with amphipathic properties designed to mimic the human immune system: anti-inflammatory, high tissue tolerance, biostability, potent against established polymicrobial biofilms and currently untreatable infections. https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/3c1c590e-8dc1-44b8-a388-825667e18484/NIH+Panviral+in+vitro+results.png Technology - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/299b807f-4ddf-4ab3-a526-73870d334db4/MXB-22%2C510+-+Human+Pathogens%2C+Horizontal+July+18%2C+2023.png Technology - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://maxwellbiosciences.com/pipeline daily 0.75 2025-07-03 https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/2868e4a1-93e5-409d-b44f-2c724c8c8065/Screenshot+2025-07-03+at+6.43.34%E2%80%AFPM.png Pipeline Diversified Commercialization Pathways & Industries: We focused only on developing medicine for almost a decade. Yet, after 10 years other industries have invited us into collaborative research and development programs projected to hit billions in revenue. We are just excited that this medicine will help heal animals, keep people’s faces clean, their bodies pure, and their kitchens pathogen-free and all while preserving their helpful microbiome. Read more about our entry into cosmetics. https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/d23f3c78-c38f-4576-8aab-2d4525617d24/Claromer+Pipeline+Report.png Pipeline Lead Drug Candidate MXB-22,510: This is an extremely broad spectrum anti-infective, effective against all tested pathogens associated with chronic rhinosinusitis. It also has the potential to disrupt the biofilms associated with Long COVID, infectious dementia, and other chronic, unmet medical needs associated with post viral syndromes and brain fungal infections. Chronic Sinusitis: According to the CDC, chronic sinusitis is suffered by around 12% of the population, causes upwards of $15B in economic costs each year, and 28,000 deaths per year in the US alone. Chronic sinusitis is often caused by combinations of fungal and bacterial infections; and there are currently no approved drugs to effectively cure this kind of infection. It is almost 100% antibiotic resistant. Current treatments for chronic sinusitis are only anti-inflammatory. Maxwell’s CLAROMER technology produces drug candidates that display extremely broad spectrum efficacy against polymicrobial infections - infections characterized by more than one bacterial and/or fungal pathogens living together in a microbial colony, generally ensconced in a antibiotic-resistant biofilm. Our lead compound has shown high potency against antibiotic-resistant bacteria and fungi, as well as biofilms. Preclinical studies have established the in vitro efficacy of Maxwell’s lead drug candidate against all sinusitis-related pathogens tested to date. And since sinusitis is potentially lethal for immunocompromised patients, the development pathway can take advantage of prioritized FDA human trials which serve to escalate solutions for lethal and completely unmet medical needs. Universal antimicrobial / Universal antiviral: Several of our platform compounds have activity against 70+ resistant bacteria and all tested fungi. Others are extremely broad spectrum antivirals against all tested strains of Ebola, influenza, and coronaviruses (including MERS, SARS-1, SARS-CoV-2), and some other viruses of future pandemic concern. https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/dc7c4563-4290-4566-8ca3-a67cd8739a01/unsplash-image-r6u-fhltchE.jpg Pipeline Independent investigators have confirmed that Maxwell’s CLAROMERS® can be tested in animals at over 50x times the therapeutic dose and still cause no toxicity. These results are important to validate the safety of our compounds at dosage levels way above what would ever be administered for therapeutic purposes. Subcutaneous Safety data in mice (confirmed in collaboration with universities and independent labs) show that CLAROMER® brand anti-infectives are were well tolerated in vivo at over 1,000 µg/mL concentration when injected under the skin; whereas, preclinical studies indicate activity against airborne viruses starting at 0.220 µg/mL concentration. This data shows a preclinical safety window thousands of times higher than the effective therapeutic dose tested in skin. Upper Airway Safety data in mice (confirmed in collaboration with universities and independent labs) show that CLAROMER® brand anti-infectives are were well tolerated in vivo at the highest levels tested (256 µg/mL concentration) when injected intratracheal; whereas, preclinical studies indicate activity against airborne viruses starting at 0.220 µg/mL concentration. This data shows a preclinical safety window 1,000 times higher than the effective therapeutic dose tested in the upper respiratory system. Human Colon Model and Donated Human Microbiome In a fabulously named study called “Colon-on-a-Plate,” we tested multiple Claromer compounds in live human colon tissue that contains donated healthy human fecal microbiome. The contract lab showed that Claromer compounds do not adversely effect the microbiome - no harm to the cells, no inhibition of healthy microbiome growth, and no adverse effect on the metabolism. So, basically no negative effects at all. Animal studies have also confirmed this in other tissues, like the sinuses. Human Lung Tissue At Texas A&M, researchers were able to show that Claromer compounds did not harm human lung tissue grown from stem cells in a special kind of container called an “air-liquid interface” which allows the lung tissue to exchange oxygen and metabolize nutrients like being inside a body. The studies showed that the compounds were very well tolerated in the human lung tissue without creating toxicity or inflammation. Animal Brains In live animals, Claromers were injected into the ear canal so that the sensitive ear neurons were dosed with the compounds. External electrodes were then attached to detect how the animals were processing sounds being processed by those neurons. The tests showed no significant difference from saline. Again, no inflammation and no toxicity even in highly sensitive ear neurons. https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/8cd3da66-16ae-4a76-884f-1132b1786bd6/Screen+Shot+2022-06-14+at+4.18.18+PM.png Pipeline https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/f950e7ff-3a52-497f-b24c-ce27fd612f38/Antibacterial+Combination+Graphic.png Pipeline https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/1617048200407-JOD1IC51JEHT57T14FZQ/In+Vivo+biodistribution+study+of+Claromers.png Pipeline https://maxwellbiosciences.com/careers-home daily 0.75 2022-11-07 https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/1594696740383-6DF5ZXITQAW60014U9IC/image-asset.jpeg https://maxwellbiosciences.com/new-page daily 0.75 2022-02-24 https://maxwellbiosciences.com/careers/investor-relations-associate daily 0.75 2022-03-01 https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/1595615848920-AUEL6AWESZS8894UT3LU/Screen+Shot+2020-07-24+at+1.37.03+PM.png Investor Relations Associate Please email your cover letter and resume to the above email address. https://maxwellbiosciences.com/team daily 0.75 2026-02-13 https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/3a5f6b00-ffe9-4e05-b76e-68a65baa60b0/Scotch+McClure+Headshot.jpg Team - Scotch McClure, MBA Founder, CEO & Chairman Mr. McClure is an engineer with over 20 years of experience as a CEO, and 10 years of experience as a corporate board director. He is a multi-patent inventor including antiviral applications of Maxwell’s platform, and human gene expression technology. His background includes leading engineering and scientific research teams, as well as military intelligence and commercial applications such as high tech hardware and software. He designed and commercialized the world’s first dual core laptop in partnership with Advanced Micro Devices. He is a pioneer in the field of plasma proteomics Big Data computation and biomimetic drug design. He has a wide ranging interest in physics, theory of mind and consciousness, information theory, nanobiology and reversing disease and aging by restoring rejuvenative homeostasis. From 1992 to 2001, he served with distinction in the United States Air Force, in highly classified financial, electronic and other intelligence project management roles at the Electronic System Center and the Air Intelligence Agency. He is a graduate of the USAF Academy with a B.S. in Management. He holds a Masters of Business Administration from the University of Massachusetts. LinkedIn https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/2f6fbda9-b584-43de-9008-e5527d64078a/Ed+New+Bio+Photo.jpg Team - Ed Rudnic, PhD COO and Head of R&D Dr. Rudnic (Ed) brings more than 30 years of diverse experience in biosciences and drug discovery. He is the former head of US R&D for Shire Pharmaceuticals where he led projects that drove over $30 billion in revenue for Shire. He has successfully raised over $500M in capital at various organizations and has successfully taken a biopharma company public on the NASDAQ. He has also been either the lead inventor or a co-inventor of 56 issued U.S. patents and numerous related international patents. Ed has held executive and leadership positions at Middlebrook Pharmaceuticals, Shire Pharmaceuticals, Vivreon Biosciences, Merck and Bristol-Myers Squibb. He holds a Bachelor of Science in Pharmacy, a Master of Science in Pharmaceutics and a Doctorate in Pharmaceutics, all from the University of Rhode Island. LinkedIn https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/1b13743c-e44e-4d91-a756-dcae96dbd870/Praveen-no-logo.jpg Team - Praveen Reddy President, International Operations Praveen brings over 20 years of experience in international government and corporate relations in Europe, India, the Middle East, Africa, and Asia to the Maxwell team. A sought after veteran of billion dollar deals in several fields, Praveen is an expert in equity investment, capital ventures, corporate finance & debt finance, mergers & acquisitions and business process re-engineering. His network of strategic relationships is built on the back of creating innovative solutions to help governments build infrastructure that sustains citizen happiness and satisfaction. His track record blends successful public-private partnerships and family offices with highly innovative affordable healthcare solutions at scale. His strong network is rooted deeply in the international arena. LinkedIn https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/83bd731b-66b1-455e-a515-6d1deebfdc36/Jon+McClure+Bio+Photo.jpg Team - Jon McClure Chief Technology Officer Jon is a seasoned technology leader with over 20 years of experience in software architecture, systems engineering and team leadership across biotech, healthcare and gaming sectors. He directed the nationwide deployment of a mission-critical patient management system for a major U.S. healthcare network, ensuring operational continuity across more than 150 hospitals during the COVID-19 pandemic. During this time, he also served as the lead engineer on ClinicalTrials.gov and MedicalCountermeasures.gov. Jon brings deep expertise in full-stack development, microservices, cloud platforms and DevOps practices to his role as CTO at Maxwell Biosciences. LinkedIn https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/54d3643d-56e2-4a24-aa27-789ef98a3a6d/Beth+Burnside+Headshot%2C+edited.jpg Team - Beth Burnside, PhD Senior Vice President, R&D Strategy Over the past 30 years, Beth has led teams in the areas of drug development and delivery, enhanced drug absorption, regulatory affairs, quality and corporate compliance, and intellectual property strategy. Invented products include Adderall XR®, Intuniv®, and MOXATAG®. Previously, she held executive roles with Lowery Creek Consulting, LLC., QRxPharma, MiddleBrook Pharmaceuticals (formerly Advancis Corporation), and Shire Laboratories, Inc. She is either the lead inventor or co-inventor on 34+ issued US patents and numerous related international patents. Beth holds a B.S. in Chemistry/Mathematics, an M.S. in Organic Chemistry, and a PhD in Physical-Organic Chemistry from Drexel University. LinkedIn https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/417301ad-fa00-417d-8492-5160a599531a/DJT+Sep+2022.jpg Team - Donald Treacy, PhD Senior Vice President, Development Operations Don brings 30 years of experience across the biotech and pharmaceutical industry, with diverse expertise across research, product development and manufacturing, and regulatory affairs. He most recently was the CEO of Magothy Consulting Group, LLC, and previously held the role of Senior Vice President of Development and Manufacturing Operations at MiddleBrook Pharmaceuticals (formerly Advancis Corporation) and Senior Director of Analytical Sciences for Shire Pharmaceuticals. Don is a named inventor on over 30 issued US and international patents in novel drug delivery, solid dosage form development and formulation performance, and has authored numerous research publications and presentations on accelerator mass spectrometry, high performance liquid chromatography and novel drug delivery systems. He holds a PhD in Analytical and Nuclear Chemistry from the University of Maryland and a B.A. in Chemistry from Roanoke College. LinkedIn https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/1d654e3f-0f07-4bb9-b713-f04001ce7bb9/LucasWenthe+Headshot+No+Tie.jpg Team - Lucas Wenthe, JD Chief Legal Officer Lucas is a dynamic company executive, blending expansive legal acumen with deep insights into diverse industries like synthetic biology and healthcare. His expertise spans the spectrum from IP strategy and patent management to mergers, acquisitions, and capital ventures. With a track record of fostering international biotech and healthcare collaborations, Lucas has also adeptly procured and licensed groundbreaking patents in medical device technologies. Lucas has a BS in computer science and is formally trained in electrical engineering. LinkedIn https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/a16c6a71-d1d2-41f2-beb9-9f8fefecf929/Tony-retouch.jpg Team - Tony Verco, MD, MBA Chief Medical Officer Tony is an anesthesiologist with over 23 years experience in the Pharmaceutical industry. He has worked in both the contract clinical research sector as well as small and large pharmaceutical companies, with experience spanning research in toxicology, pharmacology, drug safety, regulatory, commercial, and product development strategy. He has consulted to industry and managed the operational development of lead candidates from Phase 1 through Phase 3, including international phase 3 trials, in multiple therapeutic areas which included interactions with both the FDA, EMEA, and Health Canada. He combines wide and detailed experience in drug development with a broad understanding of the pharmaceutical business, having obtained an MBA in 2007. https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/4eafe239-ff54-4ade-9f94-d56bf473456b/Sheetal%252BVali%252B%25252818%252Bof%252B22%252529%252B%2525281%252529.jpg Team - Sheetal Vali, PhD Vice President, Drug Development Sheetal directs Maxwell’s drug development program and facilities a sharp focus on quality control, drug platform development, FDA Investigational New Drug enabling studies, and collaboration with contract research and manufacturing organizations. She brings deep experience and expertise in pharmaceutical product development, CMC and communications skills as well as a high degree of curiosity, innovation, entrepreneurship and a keen sense of patient unmet need. LinkedIn https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/cc90ff67-333e-4045-b94e-0b2cc2501d55/Meagan+.jpg Team - Meagan Stone, MASF Senior Director of Operations Meagan facilitates the coordination of the research pipeline data and logistics of grant projects. As a molecular biologist, she gained research experience in microbiology and genetics before joining the biotech industry. She managed laboratory operations of a CLIA-certified, established biomarker testing company in a period of rapid expansion. LinkedIn https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/c7840ddd-6c42-4847-b3ce-83ee50b502ba/Sarah+Aubrey+Headshot.jpg Team - Sarah Aubrey Senior Director of Planning Sarah invested in Maxwell as an accredited independent investor in October 2021, and has over 20 years of experience in advanced communications, including investor relations. Her background includes new deal discovery, sourcing investors and technical expertise for due diligence, managing the due diligence process, and solidifying connections between investors and management. She’s also been a music journalist, book editor, UX designer, and specialist in branding and strategy for agencies and startups in New York City, Cleveland, and Cincinnati. Some of Sarah’s former clients include Smucker’s, Airheads, Evenflo, Brown Jordan, and Legg Mason. LinkedIn https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/7bb28805-039c-48ee-a59d-ff9cba5c3f5e/_Mira+2018_RSP_4593.jpg Team - Mira Sirotic, CMA Director of Investor Relations Mira is a Maxwell investor who, for 4 years, was the Vice President at Keiretsu Forum Canada and Chair of the Deal Screening Committee. She believes in values-based servant leadership and in sharing & developing resources, experiences, and relationships that are focused on enriching the lives of others in order to build better organizations & communities. She embodies the words of Albert Einstein: "Strive not to be a success, but rather to be of value." Mira is a Certified Management Accountant (CMA) and comes to Maxwell with over 20 years of experience covering investor relations, business development, marketing & communications, raising capital investment, and financial/business reporting & analysis. LinkedIn https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/3a5f6b00-ffe9-4e05-b76e-68a65baa60b0/Scotch+McClure+Headshot.jpg Team - Scotch McClure, MBA Founder, CEO & Chairman of the Board Mr. McClure is an engineer with over 20 years of experience as a CEO, and 10 years of experience as a board director. He is a multi-patent inventor including antiviral applications of Maxwell’s platform, and human gene expression technology. His background includes leading engineering and scientific research teams, as well as military intelligence and commercial applications such as high tech hardware and software. He designed and commercialized the world’s first dual core laptop in partnership with Advanced Micro Devices. He is a pioneer in the field of plasma proteomics Big Data computation, and biomimetic drug design. He has a wide ranging interest in physics, theory of mind and consciousness, information theory, nanobiology, and reversing aging by restoring rejuvenative homeostasis. From 1992 to 2001, he served with distinction as a commission officer in the United States Air Force, in highly classified financial, electronic and other intelligence program leadership roles at the Electronic System Center and the Air Intelligence Agency. He is a graduate of the USAF Academy, with a B.S. in Management. He holds a Masters of Business Administration from the University of Massachusetts. LinkedIn https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/8effb558-c242-490e-be24-0c2a12d1fd34/Barb+Holcomb+photo+900.jpg Team - Major General (Ret.) Barbara Holcomb, RN, BSN, MSN Board Director Gen Holcomb is a retired US Army Major General. Her last assignment in 2020 was Commanding General, US Army Medical Research and Materiel Command, and Fort Detrick, and Chief of the US Army Nurse Corps. She was commander of all of the Department of Defense biodefense efforts, is one of the world’s top national security biodefense research leaders, and emergency medicine practitioner leaders. She continues to volunteer as a Registered Nurse. She brings over 33 years of experience of battlefield hospital patient care and biodefense leadership. She leads Maxwell’s partnership efforts with US Department of Defense agencies, DARPA (Defense Advanced Research Projects Agency), and BARDA (the Biomedical Advanced Research and Development Authority) as the company steps forward into leading biodefense for the US, our allies and our civilization against naturally occurring, deliberate, and accidental biological threats. Linkedin https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/4b24326e-442f-453e-ae29-1fc047df8398/Professional+Headshot+JUL2021+RET.jpg Team - Kate McKinley, MBA Board Director Ms. McKinley has over 20 years of experience in leading strategic partnerships in the biopharmaceutical industry, positioning organizations for commercial success. Ms. McKinley currently serves as Chief Business Officer of Rani Therapeutics, a clinical stage oral drug delivery platform company. She is the former Chief Executive Officer (CEO) of Elevar Therapeutics, where she played a pivotal role in fundraising and the M&A activities that led to Elevar’s acquisition by HLB, Inc. She built and led Elevar's global commercial, medical affairs, business development, manufacturing, supply chain, alliance management, and corporate communications organizations. Prior to joining Elevar, she was the Head of Marketing, Training, and the Hospital Channel at Dendreon, responsible for the first FDA approved cell-based cancer immunotherapy. Prior to Dendreon, Ms. McKinley was U.S. Head of Sales at AbbVie, overseeing new product launch planning, and market expansion strategies. Ms. McKinley is a summa cum laude graduate of The University of Tulsa. She holds an M.B.A. from the university's Collins College of Business and a Bachelor of Science in Business Administration with degrees in Marketing, Management and Psychology. In addition to serving as a board director for Maxwell Biosciences, Ms. McKinley was previously a Board Director of Elevar Therapeutics and Hainan Pactil Advanced Therapeutics Company LTD. LinkedIn https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/0a8a2b0e-4038-4255-a428-55d535b6808f/Jose+Antonio+Alas.jpg Team - José Antonio Alas Board Director Antonio Alas is a seasoned global pharmaceutical executive with over 30 years of experience in driving international business growth and strategic leadership. Based in Carmel, Indiana, he is the owner of AALAS Consulting LLC, where he leverages his expertise to coach professionals and advise pharmaceutical companies on navigating complex global business challenges. Throughout his career, Antonio has held key positions at Eli Lilly and Company, notably as President and General Manager for South Asia, the Middle East, Turkey, and Africa. In this role, he achieved unprecedented growth by executing successful product launches and forging partnerships across international markets to enhance patient access to innovative medications. Antonio earned his MBA from Duke University's Fuqua School of Business and holds a bachelor's degree in Systems and Control Engineering from the United States Naval Academy. Fluent in Spanish, English, and Portuguese, he offers a global perspective on leadership and business development, emphasizing his dedication to nurturing talent and driving commercial success. As a board member at Maxwell Biosciences and a strong advocate for talent development, Antonio continues to shape the pharmaceutical industry with his insights and strategic vision. LinkedIn https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/46e0b999-fdf1-410d-ba5e-4e8972b20542/Brad+Wenstrup.jpg Team - COL (Ret.) Brad Wenstrup, DPM Board Director From 2013 to 2025, Dr. Brad Wenstrup represented Ohio’s 2nd District in the U.S. House of Representatives and served on several key committees, including Armed Services, Veterans Affairs, Ways and Means, and the Permanent Select Committee on Intelligence, where he held multiple Chairmanships. As a leader on the Intelligence Committee, Dr. Wenstrup played a pivotal role in biodefense, he was selected as Chairman of the Select Subcommittee on the Coronavirus Pandemic and he currently serves on the President's Intelligence Advisory Board. Dr. Wenstrup is a retired Army Colonel with a distinguished record of government, military and medical service, for more than 27 years in private practice and 25 years in military medicine and surgery—with expertise in managing bacterial, fungal and viral infections. He served as the Chief of Surgery with the 344th Combat Support Hospital in Iraq and held positions at Walter Reed National Military Medical Center and as Medical Policy Advisor to the Chief of the Army Reserve. Dr. Wenstrup has worked collaboratively with agencies such as DARPA, DTRA, BARDA, NCMI, HHS, NIH, FDA, NIAID, CMS, VA, and Military Health and previously served on the Cincinnati Board of Health. LinkedIn https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/1717410350632-N9PGJO8JKFN76G73CHSZ/image-asset.jpeg Team https://maxwellbiosciences.com/about-us-1 daily 0.75 2023-02-16 https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/1593096105552-X846726BDI23S1L55BH1/AdobeStock_323031819.jpeg About Us (New) - About Us Founded in 2016, Maxwell Biosciences is a preclinical stage drug platform company actively developing an entirely new CLAROMER® biotechnology platform which creates low molecular weight compounds which mimic peptides and are functionally distinct from macromolecules due to the ease of penetrating membranes. This novel biotechnology mimics the power and flexibility of natural antimicrobial peptides - with the pharmacological advantages of a low molecular weight molecule - to safely and permanently inactivate viruses, bacteria, fungi and biofilms. Maxwell is led by a world-class team of scientists and executives. https://maxwellbiosciences.com/healthspan daily 0.75 2025-12-19 https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/0157e20e-cc5e-4e13-954d-5f7683f010ca/heterochronic+parabiosis+-+younger.png HealthSpan https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/d62cae03-2dcc-44a3-88fc-dbb2e5e1d1f3/heterochronic+parabiosis+-+old+mouse.png HealthSpan https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/1c5ecad1-bbb9-4858-a2c2-78c5b652c7d9/heterochronic+parabiosis+-+how.png HealthSpan https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/0dd16a80-5fb9-4ec4-ada1-be08b7442486/Screenshot+2023-06-26+at+4.55.56+PM.png HealthSpan https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/523817d1-1825-45ab-9839-94e843b522c2/Big+Data+Results.png HealthSpan https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/d0928cd0-ff01-4bad-a83d-ca5dabe9a45e/MEND+Gene+Expression.png HealthSpan https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/90586cc0-a6ba-4905-b75e-a89705c8bec9/LL-37+Strong+Apoptosis+Healing.png HealthSpan https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/54dc122d-18b1-4775-96d0-77748f816ccb/Peptides+Break+Down+Wide.png HealthSpan https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/9db2301e-3a7d-4021-a630-117f0dd74898/Stable+Claromer+Structure.png HealthSpan https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/1687971981356-YW6KJD1XQOIBWKBGJF4A/image-asset.jpeg https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/532fd9a3-8b67-49a7-a880-b1f9c78a89fc/Heterochronic+parabiosis+-+large+font.png https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/1687809073145-Z4OZ9TJ2XA8LFOBXGA98/image-asset.jpeg https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/fa4990cd-125f-4f34-add7-8da1ee589f9f/MXB-22%2C510+-+Human+Pathogens%2C+Horizontal+July+18%2C+2023.png https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/116315cf-6f2a-44ba-a725-fbafbe83cd04/joshua+headshot+pic.jpg https://maxwellbiosciences.com/careers-main daily 0.75 2025-06-06 https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/1594696740383-6DF5ZXITQAW60014U9IC/image-asset.jpeg https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/511a8d9b-4a08-488c-b26f-020e9277ab93/HTR+Biotech+Execs+Badge.png Careers - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/913ef815-dad5-412c-a35d-a81457bd0bca/Screenshot+2024-04-03+at+12.19.30+PM.jpg Careers https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/4fd12c6f-7d1c-410b-b339-d28e51fe8486/Screenshot+2024-04-03+at+12.41.09+PM.jpg Careers https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/1f4b13c3-b96a-4759-a0ac-4052f515ad77/Badge+-+Most+Promising.jpg Careers https://maxwellbiosciences.com/healthspan-1 daily 0.75 2025-05-07 https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/d62cae03-2dcc-44a3-88fc-dbb2e5e1d1f3/heterochronic+parabiosis+-+old+mouse.png HealthSpan (Copy) https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/0157e20e-cc5e-4e13-954d-5f7683f010ca/heterochronic+parabiosis+-+younger.png HealthSpan (Copy) https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/1c5ecad1-bbb9-4858-a2c2-78c5b652c7d9/heterochronic+parabiosis+-+how.png HealthSpan (Copy) https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/0dd16a80-5fb9-4ec4-ada1-be08b7442486/Screenshot+2023-06-26+at+4.55.56+PM.png HealthSpan (Copy) https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/523817d1-1825-45ab-9839-94e843b522c2/Big+Data+Results.png HealthSpan (Copy) https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/d0928cd0-ff01-4bad-a83d-ca5dabe9a45e/MEND+Gene+Expression.png HealthSpan (Copy) https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/90586cc0-a6ba-4905-b75e-a89705c8bec9/LL-37+Strong+Apoptosis+Healing.png HealthSpan (Copy) https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/54dc122d-18b1-4775-96d0-77748f816ccb/Peptides+Break+Down+Wide.png HealthSpan (Copy) https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/9db2301e-3a7d-4021-a630-117f0dd74898/Stable+Claromer+Structure.png HealthSpan (Copy) https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/1687971981356-YW6KJD1XQOIBWKBGJF4A/image-asset.jpeg https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/532fd9a3-8b67-49a7-a880-b1f9c78a89fc/Heterochronic+parabiosis+-+large+font.png https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/1687809073145-Z4OZ9TJ2XA8LFOBXGA98/image-asset.jpeg https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/fa4990cd-125f-4f34-add7-8da1ee589f9f/MXB-22%2C510+-+Human+Pathogens%2C+Horizontal+July+18%2C+2023.png https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/116315cf-6f2a-44ba-a725-fbafbe83cd04/joshua+headshot+pic.jpg https://maxwellbiosciences.com/cosmetics daily 0.75 2026-03-23 https://maxwellbiosciences.com/subscribe daily 0.75 2025-05-21 https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/1747830418638-Q4V6NHTURIJSVTBDAAM9/unsplash-image-Q1p7bh3SHj8.jpg https://maxwellbiosciences.com/subscribetagging daily 0.75 2025-12-16 https://images.squarespace-cdn.com/content/v1/5ed6e477b011a123217bcd36/1747830418638-Q4V6NHTURIJSVTBDAAM9/unsplash-image-Q1p7bh3SHj8.jpg